MannKind is a biopharmaceutical company best known for Afrezza, an ultra-rapid-acting insulin delivered by oral inhalation rather than injection, and for its Technosphere particle technology that enables pulmonary drug delivery. It develops and commercializes therapies and partners its delivery platform for additional molecules. The company primarily serves people with diabetes and partners in the broader respiratory and peptide delivery space.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 76.5 | — | 0.7 | — |
| Q3 2025 | 82.1 | — | 8 | — |
| Q4 2025 | 112 | — | -15.9 | — |
| Q1 2026 | 90.2 | — | -16.6 | — |
| Q2 2026 | 109.4 | 42.9% | -19 | -2,949.1% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Vor Biopharma Inc. (VOR), Castle Biosciences, Inc. (CSTL), Evolution Metals & Technologies Corp. (EMAT), CeriBell, Inc. (CBLL), Sigma Lithium Corporation (SGML), NB Bancorp, Inc. (NBBK)